> Detailanzeige

Dietlein, Felix [VerfasserIn]; Hohberg, Melanie [VerfasserIn]; Drzezga, Alexander [VerfasserIn]; Dietlein, Markus [VerfasserIn]; Kobe, Carsten [VerfasserIn]; Zlatopolskiy, Boris D. [VerfasserIn]; Krapf, Philipp [VerfasserIn]; Endepols, Heike [VerfasserIn]; Täger, Philipp [VerfasserIn]; Hammes, Jochen [VerfasserIn]; Heidenreich, Axel [VerfasserIn]; Neumaier, Bernd [VerfasserIn]

An 18 F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18 F-JK-PSMA-7 During the First Year of Application

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: An 18 F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18 F-JK-PSMA-7 During the First Year of Application
  • Beteiligte: Dietlein, Felix [VerfasserIn]; Hohberg, Melanie [VerfasserIn]; Drzezga, Alexander [VerfasserIn]; Dietlein, Markus [VerfasserIn]; Kobe, Carsten [VerfasserIn]; Zlatopolskiy, Boris D. [VerfasserIn]; Krapf, Philipp [VerfasserIn]; Endepols, Heike [VerfasserIn]; Täger, Philipp [VerfasserIn]; Hammes, Jochen [VerfasserIn]; Heidenreich, Axel [VerfasserIn]; Neumaier, Bernd [VerfasserIn]
  • Erschienen: Soc., 2020
  • Erschienen in: Journal of nuclear medicine 61(2), 202 - 209 (2020). doi:10.2967/jnumed.119.229542
  • Sprache: Englisch
  • DOI: https://doi.org/10.2967/jnumed.119.229542
  • ISSN: 2159-662X; 1535-5667; 0097-9058; 0161-5505; 0022-3123
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. The aim of this study was to evaluate the clinical utility of 18F-JK-PSMA-7 for PET/CT imaging of patients with prostate cancer. Methods: In an Institutional Review Board–approved pilot study, the initial clinical utility of PET/CT imaging with 18F-JK-PSMA-7 was directly compared with 68Ga-PSMA-11 PET/CT in a group of 10 patients with prostate cancer. The 2 PSMA tracers were administered to each patient less than 3 wk apart. Next, we analyzed the data of 75 consecutive patients who had undergone clinical 18F-JK-PSMA-7 PET/CT imaging for tumor localization of biochemical recurrence (BCR). Results: The pilot study in 10 patients who were examined with both PSMA tracers demonstrated that 18F-JK-PSMA-7 was at least equivalent to 68Ga-PSMA-11. All unequivocally 68Ga-PSMA-11–positive lesions could be also detected using 18F-JK-PSMA-7, and in 4 patients additional suspected PSMA-positive lesions were identified (1 patient changed from PSMA-negative to PSMA-positive). In patients with BCR (after prostatectomy or radiotherapy), the capacity of 18F-JK-PSMA-7 PET/CT to detect at least one PSMA-positive lesion was 84.8%. The prostate-specific antigen (PSA)–stratified detection rate of 18F-JK-PSMA-7 after prostatectomy varied among 54.5% (6/11 patients; PSA < 0.5 μg/L), 87.5% (14/16 patients; PSA 0.5–2 μg/L), and 90.9% (20/22 patients; PSA > 2 μg/L). Conclusion: The tracer 18F-JK-PSMA-7 was found to be safe and clinically useful. We demonstrated that 18F-JK-PSMA-7 was not inferior when directly compared with 68Ga-PSMA-11 in a pilot study but indeed identified additional PSMA-avid suspected lesions in oligometastasized patients with BCR. In a subsequent analysis of a clinical cohort of BCR patients, 18F-JK-PSMA-7 was useful in tumor localization. 18F-JK-PSMA-7 is recommended for future prospective ...
  • Zugangsstatus: Freier Zugang